Funding announcement
Vaxxas Announces Initiation of Phase I Clinical Study of First Needle-Free COVID-19 Vaccine Delivered Using High-Density Microarray Patch (HD-MAP)
Vaxxas has begun an Australian Phase I trial of its needle-free COVID-19 vaccine patch, built on a University of Texas at Austin candidate; the article also recalls the company's early financings led by OneVentures.